p.108 抽出テキスト

testing in relatives of LQTS probands. Circulation 2011; 124: 2187-2194. PMID: 22042885 136. Abrahams T, Davies B, Laksman Z, et al. Provocation testing in congenital long QT syndrome: A practical guide. Heart Rhythm 2023; 20: 1570-1582. PMID: 37481219 137. Yang Y, Lv TT, Li SY, et al. Utility of Provocative Testing in the Diagnosis and Genotyping of Congenital Long QT Syndrome: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2022; 11: e025246. PMID: 35861842 138. Page A, Aktas MK, Soyata T, et al. “QT clock” to improve detection of QT prolongation in long QT syndrome patients. Heart Rhythm 2016; 13: 190-198. PMID: 26334569 139. Yodogawa K, Aiba T, Sumitomo N, et al. Differential diagnosis between LQT1 and LQT2 by QT/RR relationships using 24-hour Holter monitoring: A multicenter cross-sectional study. Ann Noninvasive Electrocardiol 2021; 26: e12878. PMID: 34245193 140. Avari Silva JN, Bromberg BI, Emge FK, et al. Implantable Loop Recorder Monitoring for Refining Management of Children With Inherited Arrhythmia Syndromes. J Am Heart Assoc 2016; 5: e003632. PMID: 27231019 141. Nakayama H, Aiba T, Miyazaki Y, et al. Implantable loop recorder uncovered torsades de pointes in long-QT syndrome type 1 with multi cause of syncope. J Cardiol Cases 2024; 29: 214-217. PMID: 39100517 142. Behr ER, Winkel BG, Ensam B, et al. The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy, the Association of European Paediatric and Congenital Cardiology (AEPC), the Paediatric & Congenital Electrophysiology Society (PACES), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace 2025; 27: euaf067. PMID: 40165484 143. Vink AS, Hermans BJM, Hooglugt JQ, et al. Diagnostic Accuracy of the Standing Test in Adults Suspected for Congenital Long-QT Syndrome. J Am Heart Assoc 2023; 12: e026419. PMID: 37421262 144. Yoshinaga M, Kamimura J, Fukushige T, et al. Face immersion in cold water induces prolongation of the QT interval and T-wave changes in children with nonfamilial long QT syndrome. Am J Cardiol 1999; 83: 1494-1497. PMID: 10335770 145. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol 2007; 49: 329-337. PMID: 17239714 146. Mazzanti A, Maragna R, Vacanti G, et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. J Am Coll Cardiol 2018; 71: 1663-1671. PMID: 29650123 147. Yang J, Luo J, Li K, et al. T-Wave Alternans Measured by 24-Hour Ambulatory Recordings Rather Than Exercise Stress Tests as a Risk Stratification Marker in Patients With Long QT Syndrome. J Am Heart Assoc 2024; 13: e033619. PMID: 38979841 148. Zareba W, Moss AJ, le Cessie S, et al. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol 1994; 23: 1541-1546. PMID: 8195511 149. Cruz Filho FE, Maia IG, Fagundes ML, et al. Electrical behavior of T-wave polarity alternans in patients with congenital long QT syndrome. J Am Coll Cardiol 2000; 36: 167-173. PMID: 10898429 150. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-1874. PMID: 12736279 151. Bjelic M, Goldenberg I, Younis A, et al. Risk Prediction in Male Adolescents With Congenital Long QT Syndrome: Implications for Sex-Specific Risk Stratification in Potassium Channel-Mediated Long QT Syndrome. J Am Heart Assoc 2024; 13: e028902. PMID: 38240206 152. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101: 616-623. PMID: 10673253 153. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol 2009; 54: 832-837. PMID: 19695463 154. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol 2010; 55: 783-788. PMID: 20170817 155. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with betablockers. JAMA 2004; 292: 1341-1344. PMID: 15367556 156. Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differ- ences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004; 44: 117-125. PMID: 15234419 157. Schwartz PJ, Moreno C, Kotta MC, et al. Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. Eur Heart J 2021; 42: 4743- 4755. PMID: 34505893 158. Kashiwa A, Itoh H, Makiyama T, et al. Clinical characterization of type 1 long QT syndrome caused by C-terminus Kv7.1 variants. Heart Rhythm 2024; 21: 1113-1120. PMID: 38367891 159. Aizawa T, Wada Y, Hasegawa K, et al. Non-missense variants of KCNH2 show better outcomes in type 2 long QT syndrome. Europace 2023; 25: 1491-1499. PMID: 36861347 160. Blich M, Khoury A, Suleiman M, et al. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation. Int Heart J 2019; 60: 979-982. PMID: 31257342 161. Yokoyama Y, Aiba T, Ueda N, et al. Subcutaneous and transvenous implantable cardioverter defibrillator in high-risk long-QT syndrome type 3 associated with Val411Met mutation in SCN5A. J Cardiol Cases 2020; 22: 238-241. PMID: 33133318 162. Liu JF, Moss AJ, Jons C, et al. Mutation-specific risk in two genetic forms of type 3 long QT syndrome. Am J Cardiol 2010; 105: 210-213. PMID: 20102920 163. Delannoy E, Sacher F, Maury P, et al. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. Europace 2013; 15: 1805-1811. PMID: 23867365 164. Kato K, Higo Y, Aizawa T, et al. Long-Term Arrhythmic Outcomes of KCNJ2 Variant Carriers in Japan. Circ Genom Precis Med 2025; 18: e005188. PMID: 41025222 165. Mazzanti A, Trancuccio A, Kukavica D, et al. Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). Europace 2022; 24: 614-619. PMID: 34505884 166. University of Pavia, Istituti Clinici Scientifici Maugeri. 1-2-3 LQTS Risk calculator. https://1-2-3-lqt.unipv.it/ 167. Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverterdefibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010; 122: 1272-1282. PMID: 20837891 168. Dusi V, Dagradi F, Spazzolini C, et al. Long QT syndrome: importance of reassessing arrhythmic risk after treatment initiation. Eur Heart J 2024; 45: 2647-2656. PMID: 38751064 169. Kitajima R, Aiba T, Kamakura T, et al. Landiolol suppression of electrical storm of torsades de pointes in patients with congenital long-QT syndrome type 2 and myocardial ischemia. J Arrhythm 2017; 33: 501-504. PMID: 29021858 170. Shimizu W, Ohe T, Kurita T, et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 1995; 26: 1299-1309. PMID: 7594047 171. Tobert KE, Bos JM, Garmany R, et al. Return-to-Play for Athletes With Long QT Syndrome or Genetic Heart Diseases Predisposing to Sudden Death. J Am Coll Cardiol 2021; 78: 594-604. PMID: 34330632 172. Martinez KA, Bos JM, Baggish AL, et al. Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death. J Am Coll Cardiol 2023; 82: 661-670. PMID: 37587576 173. Lampert R, Day S, Ainsworth B, et al. Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study. Circulation 2024; 150: 516-530. PMID: 39051104 174. Lampert R, Chung EH, Ackerman MJ, et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play. Heart Rhythm 2024; 21: e151-e252. PMID: 38763377 175. Younis A, Bos JM, Zareba W, et al. Association Between Syncope Trigger Type and Risk of Subsequent Life-Threatening Events in Patients With Long QT Syndrome. JAMA Cardiol 2023; 8: 775-783. PMID: 37436769 176. Hermida A, Gourraud JB, Denjoy I, et al. Type 3 long QT syndrome: Is the effectiveness of treatment with beta-blockers population-specific? Heart Rhythm 2024; 21: 313-320. PMID: 37956775 177. Chockalingam P, Crotti L, Girardengo G, et al. Not all betablockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll